---

Market Overview

---

The US HIV rapid test kits market demonstrated a value of $434.7 million in 2022 and is projected to reach $486.3 million by 2028, with a compound annual growth rate (CAGR) of 1.89% during the study period.

HIV rapid test kits are in-vitro diagnostics (IVD) products designed to detect the presence or exposure to the human immunodeficiency virus (HIV) in blood, oral fluid (saliva), and urine. These tests provide results within 20-30 minutes. Some HIV rapid test kits are self-tests that can be conveniently used at home or in private settings. These kits are widely accepted and serve as important tools for HIV diagnosis and preventive measures. They reduce the need for laboratory visits and offer greater convenience for individuals.

A significant trend in the US market is the increasing popularity of fourth-generation rapid test kits, which are more accurate and reliable in screening for acute HIV presence in samples. Compared to older-generation technologies, fourth-generation HIV tests deliver faster and more precise results.

Conventional rapid diagnostic tests (RDTs) carry the risk of result misinterpretation, particularly influenced by the interpreter’s experience and environmental factors such as lighting conditions. To address this concern, there is a growing interest in replacing visual labels used in lateral flow assays (LFAs) with upconverting nanoparticles (UCNPs). The use of UCNPs in LFAs offers several advantages, including improved analytical sensitivity due to the unique photoluminescence properties of UCNPs. The application of UCNPs in HIV detection is gaining momentum and is expected to drive the adoption of HIV rapid test kits.

---

Market Segmentation

---

The market is segmented based on various factors, including technology type, sample type, and distribution channel type.

Segmentation by Technology Type
Lateral Flow Immunoassay
Immuno-filtration

Segmentation by Sample Type
Blood
Oral Fluid
Others

Segmentation by Distribution Channel Type
Offline
Online

The lateral flow immunoassay segment held a significant market share of 81.37% in the US HIV rapid test kits market in 2022. Lateral flow immunoassay tests are widely used as rapid diagnostic tests, with millions of these tests performed annually. These tests have gained popularity due to their potential in supporting near-person testing and decentralized management of various clinically important diseases, including HIV. This convenience for end users and affordability for healthcare systems has contributed to its widespread adoption.

Among the sample types, the blood segment accounted for a major share of 63.12% in the US HIV rapid test kits market in 2022. Rapid test kits that utilize blood samples are commonly employed for early detection of HIV. These kits operate on the principle that when antibodies from an HIV-infected individual encounter HIV antigens, an Ag-Ab reaction occurs. Key players such as OraSure Technologies, Trinity Biotech, Bio-Rad Laboratories, and bioLytical Laboratories offer HIV rapid test kits based on blood samples.

The offline distribution channel segment held a significant share of 63.63% in the US HIV rapid test kits market in 2022. Offline sales channels encompass medical shops, pharmacies, hospitals, clinic-associated pharmacies, and pharma retailers. Medical pharmacies serve as primary points of care for HIV rapid test kit purchases. Ease of access, availability, and buyer convenience are major factors driving sales through offline channels.

---

Competitive Landscape

---

Prominent participants in the HIV rapid test kits market include Abbott, OraSure Technologies, Bio-Rad Laboratories, Chembio Diagnostics, Biomerieux, and several others. The market for HIV rapid test kits in the United States is characterized by intense competition, with various global players offering a diverse range of products. To enter this market and gain access to commercially launched products, major players are strategically engaging in acquisitions, licensing agreements, and collaborations with emerging players.

Key companies profiled in this report include Abbott, Bio-Rad Laboratories, Biomerieux, Chembio Diagnostics, OraSure Technologies, biolytical Laboratories, Biosynex, DIALAB, HUMAN Diagnostics, Intec Inc, J.Mitra & Co.,, Meril Life Sciences, MP Biomedicals, Medsource Ozone Biomedicals, Premier Medicals, SD Biosensor, Turklab AS, Trinity Biotech.

---

Key Questions Answered

---

What was the market size of HIV rapid test kits in the United States in 2022?
What are the significant trends influencing the growth of the HIV rapid test kits market in the United States?
Who are the key players in the HIV rapid test kits market?
Which sample type segment dominates the HIV rapid test kits market in the United States?
Who are the other prominent vendors in the HIV rapid test kits market in the United States?
How is each market segment expected to grow during the forecast period?
What will be the compound annual growth rate (CAGR) of the HIV rapid test kits market in the United States during the forecast period (2023-2028)?
Which distribution channel holds a larger market share in the HIV rapid test kits market in the United States?
Which technology type segment is the major contributor to the HIV rapid test kits market in the United States?
What are the driving factors, restraints, and opportunities in the HIV rapid test kits market in the United States?